🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 9 of 15

  1. SALINE, OTHER PLASMA PROTEIN FRACTIONS , Octaplasma 45-70 mg/ml pulver og væske til infusjonsvæske, oppløsning, Saline (NaCl)

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  2. SK-PC-B70M

    Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  3. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  4. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  5. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  6. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  7. SUL-238, Identical to test product except without active substance

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  8. SYNTOCINON 40 i.e./ml pršilo za nos, raztopina, Oxytocin Placebo

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  9. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  10. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  11. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  12. Solriamfetol

    Axsome Therapeutics

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  13. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  14. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  15. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  17. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  18. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  19. TNX-601 ER

    Tonix Pharmaceuticals Holding

    Depression

    phase 2 small molecule completed

    1 trial

  20. TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  21. TPM XR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  22. Talampanel

    Teva Pharma GmbH

    Epilepsy

    phase 2 small molecule completed

    1 trial

  23. TolDec

    The George Institute

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  24. Trontinemab, Placebo Trontinemab, Flortaucipir F18

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  25. UB-311

    United Therapeutics Europe Ltd

    Alzheimer's Disease

    phase 2 mab terminated

    3 trials

  26. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  27. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  28. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial

  29. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  30. VY7523

    Voyager Therapeutics

    Alzheimer's Disease (AD)

    phase 2 small molecule active

    1 trial

  31. Venlafaxine

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  32. Vitamin D3

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 other completed

    1 trial

  33. Wei Li Bai capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  34. XPF-010, XPF-008, XEN1101 placebo

    Xenon Pharmaceuticals

    Adult focal (partial onset) epilepsy

    phase 2 small molecule active

    1 trial

  35. YTB323, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  36. [123I] 5-IA

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  37. [123I]B-CIT

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  38. [123I]β-CIT

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  39. [18F]PI-2620

    The George Institute

    Down Syndrome, Alzheimer disease

    phase 2 small molecule active

    1 trial

  40. [18F]PI-2620

    The George Institute

    Down Syndrome., Alzheimer´s Disease.

    phase 2 small molecule active

    1 trial

  41. [18F]PI-2620

    The George Institute

    Progressive supranuclear palsy, Parkinson's disease

    phase 2 small molecule active

    1 trial

  42. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  43. armodafinil

    Teva Pharma GmbH

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  44. ataluren

    PTC THERAPEUTICS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  45. fetal nigral transplantation

    Ultragenyx UK Limited

    Parkinson Disease

    phase 2 other completed

    1 trial

  46. florquinitau F18, JNJ-64042056, JNJ-64042056

    Janssen-Cilag International N.V.

    Preclinical Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  47. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  48. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapse-Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.